Results 1 to 10 of about 5,165 (152)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System

Frontiers in Pharmacology, 2022
Esketamine was approved for the treatment of treatment-resistant depression in 2019. After the approval of esketamine, numerous concerns have been raised regarding its long-term safety and tolerability.
Jisheng Wang
exaly   +3 more sources

Global Trends and Hotspots in Esketamine Research: A Bibliometric Analysis of Past and Estimation of Future Trends

Drug Design, Development and Therapy, 2022
Xiang Li,1 Ping Xiang,2 Jianfen Liang,1 Yifan Deng,1 Jingyi Du1 1Department of Anesthesiology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, People’s Republic of China; 2Department of Medical Quality Management, Nanfang ...
Ping Xiang, Yifan Deng, Jingyi Du
exaly   +2 more sources

Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series [PDF]

European Journal of Psychotraumatology
Background: Posttraumatic stress disorder (PTSD) is a severe and frequent affection that is highly comorbid to major depressive disorder. Comorbid PTSD and depression increase the risk of treatment-resistant depression (TRD), with a high risk of ...
Maud Rothärmel, Lila Mekaoui, François Kazour, Morgane Herrero, Eva-Maria Beetz-Lobono, Aiste Lengvenyte, Jérôme Holtzmann, Philippe Raynaud, Macarena Cuenca, Samuel Bulteau, Pierre De Maricourt, Thomas Husson, Emilie Olié, Bénédicte Gohier, Anne Sauvaget, Raphaël Gaillard, Raphaëlle Richieri, David Szekely, Ludovic Samalin, Olivier Guillin, Virginie Moulier, Wissam El-Hage, Andrew Laurin, Lucie Berkovitch   +23 more
doaj   +2 more sources

Clinical applications of esketamine: Current status and future perspectives [PDF]

Journal of International Medical Research
Ketamine, a dissociative anesthetic, has been extensively used in clinical anesthesia and sedation. However, its use in general anesthesia is gradually declining because of numerous adverse effects.
Hui Li, Jingjing Deng, Tao Liu, Yuenong Zhang   +3 more
doaj   +2 more sources

Intermittent versus continuous esketamine infusions for long-term pain modulation in complex regional pain syndrome: protocol of a randomized controlled non-inferiority study (KetCRPS-2)

BMC Musculoskeletal Disorders, 2023
Background Complex regional pain syndrome (CRPS) is a chronic pain condition of an extremity. While achieving pain relief in CRPS is challenging, esketamine infusions can accomplish pain relief for several weeks post-infusion in a subgroup of CRPS ...
Thomas J. P. Mangnus, Maaike Dirckx, Krishna D. Bharwani, Sara J. Baart, Theodora A. M. Siepman, Ken Redekop, Willem A. Dik, Cecile C. de Vos, Frank J. P. M. Huygen   +8 more
doaj   +1 more source

Midazolam Attenuates Esketamine-Induced Overactive Behaviors in Mice Before the Sedation, but Not During the Recovery

Frontiers in Veterinary Science, 2022
Esketamine showed more potency, more rapid recovery from anesthesia, and less psychotomimetic side effects when compared with ketamine. However, the patients still experience psychotomimetic side effects of esketamine.
Qinjun Chu, Meng Mao, Yafan Bai, Liwei Sun, Dongqing Zhang, Ping Zheng, Xiaogao Jin, Xiaogao Jin, Xiaogao Jin, Xiaogao Jin   +9 more
doaj   +1 more source

Efficacy and safety of esketamine for sedation among patients undergoing gastrointestinal endoscopy: a systematic review and meta-analysis

BMC Anesthesiology, 2023
Background Patients who undergo gastrointestinal endoscopy often require propofol-based sedation combined with analgesics. At present, the efficacy and safety of esketamine as an adjunct to propofol for sedation during endoscopic procedures in patients ...
Xianghong Lian, Yunzhu Lin, Ting Luo, Yang Jing, Hongbo Yuan, Yixin Guo   +5 more
doaj   +1 more source

Exploring the role of esketamine in alleviating depressive symptoms in mice via the PGC-1α/irisin/ERK1/2 signaling pathway

Scientific Reports, 2023
Esketamine provides an immediate and noticeable antidepressant effect, although the underlying molecular processes are yet unclear. Irisin induced by aerobic exercise has been implicated in the alleviation of depressive symptoms, whether irisin ...
Na Hu, Xuemei Chen, Chengchuan Chen, Xing Liu, Peng Yi, Tianhao Xu, Jing Jia, Jianguo Feng, Chunxiang Zhang, Xiaobin Wang   +9 more
doaj   +1 more source

Esketamin [PDF]

pharma-kritik, 2021
In Form eines Nasensprays (Spravato®) ist das S-Enantiomer von Ketamin zur Behandlung einer «therapieresistenten» Depression zugelassen. Hinsichtlich der psychischen Auswirkungen teilt diese Form die Eigenschaften von Ketamin.
openaire   +1 more source

Subanaesthetic dose of esketamine during induction delays anaesthesia recovery a randomized, double-blind clinical trial

BMC Anesthesiology, 2022
Background Esketamine is an antagonist of the N-methyl-D-aspartate receptor (NMDA receptor) that is widely used for multimodal analgesia. In addition to analgesia, sedation is another important effect of esketamine.
Cao Zhang, Jiangqin He, Qinye Shi, Fangping Bao, Jianhong Xu   +4 more
doaj   +1 more source